BioCentury
ARTICLE | Clinical News

Viaskin rPT: Ph I ongoing

November 30, 2016 4:16 PM UTC

An independent DSMB recommended continuation to the 50 µg cohort of Viaskin rPT in a double-blind, placebo-controlled, Swiss Phase I trial evaluating 48-hour applications of 25 and 50 µg Viaskin rPT g...